Notable Runner: Today BioTime, Inc. Stock Crashes

Notable Runner: Today BioTime, Inc. Stock Crashes

The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! The stock decreased 2.17% or $0.07 on November 30, hitting $3.15. About 328,004 shares traded hands or 52.45% up from the average. BioTime, Inc. (NYSEMKT:BTX) has risen 6.62% since April 27, 2016 and is uptrending. It has outperformed by 1.40% the S&P500.
The move comes after 5 months negative chart setup for the $321.69M company. It was reported on Nov, 30 by We have $3.02 PT which if reached, will make NYSEMKT:BTX worth $12.87 million less.

Analysts await BioTime, Inc. (NYSEMKT:BTX) to report earnings on March, 21. They expect $-0.18 earnings per share, down 12.50% or $0.02 from last year’s $-0.16 per share. After $-0.08 actual earnings per share reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 125.00% negative EPS growth.

According to Zacks Investment Research, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.”

Insitutional Activity: The institutional sentiment increased to 2.67 in 2016 Q2. Its up 0.42, from 2.25 in 2016Q1. The ratio is positive, as 3 funds sold all BioTime, Inc. shares owned while 13 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 38.13 million shares or 10.80% more from 34.42 million shares in 2016Q1.
Granite Point Cap L P reported 78,792 shares or 0.09% of all its holdings. Fifth Third Financial Bank has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Nationwide Fund holds 0% or 37,493 shares in its portfolio. Guggenheim Cap Ltd Co last reported 0% of its portfolio in the stock. Vantage Inv Advsrs Ltd last reported 0% of its portfolio in the stock. California State Teachers Retirement holds 0% or 134,039 shares in its portfolio. Teachers Incorporated holds 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX) for 92,984 shares. One Trading Lp owns 6,794 shares or 0% of their US portfolio. Perceptive Advsrs Ltd Liability Corporation holds 13,740 shares or 0% of its portfolio. Teacher Retirement Systems Of Texas holds 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX) for 5,362 shares. Rhumbline Advisers holds 48,181 shares or 0% of its portfolio. Family Management reported 93,500 shares or 0.14% of all its holdings. Carroll Assocs last reported 17,000 shares in the company. Broadwood Capital Inc, a New York-based fund reported 24.90 million shares. Citigroup Inc has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX).

More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: which released: “BioTime, Inc. to Report Second Quarter Results on August 9, 2016” on July 27, 2016, also with their article: “Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring …” published on January 12, 2016, published: “News BioTime Inc.BTX” on February 12, 2011. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: and their article: “BioTime, Inc. Announces Proposed Public Offering of Common Stock” published on June 15, 2016 as well as‘s news article titled: “BioTime, Inc. Announces Pricing of Public Offering of Common Stock” with publication date: June 16, 2016.

BTX Company Profile

BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment